
OSI-930
CAS No. 728033-96-3
OSI-930 ( OSI 930 | OSI930 )
产品货号. M15785 CAS No. 728033-96-3
一种有效的口服活性 c-Kit 和 VEGFR-2 (KDR) 双重抑制剂,IC50 分别为 15 nM 和 9 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥535 | 有现货 |
![]() ![]() |
5MG | ¥834 | 有现货 |
![]() ![]() |
10MG | ¥1418 | 有现货 |
![]() ![]() |
25MG | ¥2746 | 有现货 |
![]() ![]() |
50MG | ¥4666 | 有现货 |
![]() ![]() |
100MG | ¥6683 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称OSI-930
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的口服活性 c-Kit 和 VEGFR-2 (KDR) 双重抑制剂,IC50 分别为 15 nM 和 9 nM。
-
产品描述A potent, orally active, dual inhibitor of c-Kit and VEGFR-2 (KDR) with IC50 of 15 nM and 9 nM, respectively; also inhibits Lck, c-Raf, Flt1, and CSF-1R (IC50<100 nM); exhibits antitumor activity in mutant Kit-expressing HMC-1 xenograft model.Solid Tumors Phase 1 Discontinued(In Vitro):OSI-930 inhibits cell proliferation in the HMC-1 cell line with IC50 of 14 nM but has no significant effect on the growth of COLO-205 cell line that does not express constitutively active mutant receptor tyrosine kinase. OSI-930 induces apoptosis in HMC-1 cell line with an EC50 value of 34 nM. OSI-930 inactivates purified, recombinant cytochrome P450 3A4 with a Ki of 24 μM in a time- and concentration-dependent manner.(In Vivo):OSI-930 (oral gavage; once a day; 38 days; 200 mg/kg) exhibits potent antitumor activity in a broad range of preclinical xenograft models.
-
体外实验OSI-930 inhibits cell proliferation in the HMC-1 cell line with IC50 of 14 nM but has no significant effect on the growth of COLO-205 cell line that does not express constitutively active mutant receptor tyrosine kinase. OSI-930 induces apoptosis in HMC-1 cell line with an EC50 value of 34 nM.OSI-930 inactivates purified, recombinant cytochrome P450 3A4 with a Ki of 24 μM in a time- and concentration-dependent manner
-
体内实验OSI-930 (oral gavage; once a day; 38 days; 200 mg/kg) exhibits potent antitumor activity in a broad range of preclinical xenograft models. Animal Model:Female nu/nu CD-1 mice bearing HMC-1, NCI-SNU-5, COLO-205 and U251 xenograft models Dosage:200 mg/kg Administration:Oral gavage; once a day; 38 days Result:Showed a significant level of inhibition of Kit, KDR and CSF-1R.
-
同义词OSI 930 | OSI930
-
通路Angiogenesis
-
靶点c-Kit
-
受体C-Raf|CSF-1R|FLT1|Lck|VEGFR2?(KDR)
-
研究领域Cancer
-
适应症Solid Tumors
化学信息
-
CAS Number728033-96-3
-
分子量443.4416
-
分子式C22H16F3N3O2S
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C(C1=C(NCC2=CC=NC3=CC=CC=C23)C=CS1)NC4=CC=C(OC(F)(F)F)C=C4
-
化学全称2-Thiophenecarboxamide, 3-[(4-quinolinylmethyl)amino]-N-[4-(trifluoromethoxy)phenyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Garton AJ, et al. Cancer Res. 2006 Jan 15;66(2):1015-24.
2. Yap TA, et al. Clin Cancer Res. 2013 Feb 15;19(4):909-19.
3. Patel JP, et al. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6495-9.
4. Macpherson IR, et al. Eur J Cancer. 2013 Mar;49(4):782-9.
产品手册




关联产品
-
CHMFL-KIT-031
CHMFL-KIT-031 是一种高选择性 KIT 激酶主要 V559D 突变抑制剂,IC50/Kd 为 28/266 nM。
-
AZD2932
AZD2932是一系列新的喹唑啉醚抑制剂,可有效抑制VEGFR-2和PDGFR,对PDGFRβ/VEGFR-2/Flt-3的IC50为4 nM/8 nM/ 7 nM。
-
INCB024360 analogue
IDO-IN-2 是一种有效的 IDO1 抑制剂(IC50=10 nM)。